

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	10/561,973
Filing Date	December 22, 2005
First Named Inventor	Kazuyuki OHMOTO
Art Unit	1625
Examiner Name	Rita J DESAI
Attorney Docket Number	Q92245

U.S. PATENTS

Examiner Initials*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1	4336260	A	1982-06-22		

U.S. PATENT APPLICATION PUBLICATIONS

Examiner Initials*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1	2008-0114012	A1	2008-05-15	Kazuyuki OHMOTO, et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁵
	1	2004-501919	JP	A	2004-01-22	Riri Aikosu Ltd., et al.		Corresponds to WO 2002/00657
	2	3-287586	JP	A	1991-12-18	Taisho Pharmaceutical Co., Ltd.		
	3	02-00657	WO	A2	2002-01-03	LILLY ICOS LLC.		Corresponds to JP 2004-501919
	4	02-064590	WO	A2	2002-08-22	LILLY ICOS LLC		Corresponds to JP-2004-518729
	5	00-15639	WO	A1	2000-03-23	ICOS CORP.		Corresponds to JP-2002-524564
	6	99-64420	WO	A1	1999-12-16	Societe de Conseils de Recherches et D'Applications Scientifiques S.A.		Corresponds to JP-2002-517500
	7	95-26723	WO	A1	1995-10-12	Interneuron Pharmaceuticals, I		Corresponds to JP-9-511246
	8	02-064591	WO	A2	2002-08-22	LILLY ICOS LLC.		Corresponds to JP-2004-518730
	9	1475368	EP	A1	2004-11-10	Ono Pharmaceutical Co., Ltd.		
	10	2004-113300	WO	A1	2001-12-29	Ono Pharmaceutical Co., Ltd.		
	11	2004-532852	JP	A	2004-10-28	Riri Aikosu Ltd., et al.		
	12	2004-518730	JP	A	2004-06-24	Riri Aikosu Ltd., et al.		
	13	2002-524564	JP	A	2002-08-06	ICOS Corp.		Corresponds to WO 2000/015639
	14	2002-517500	JP	A	2002-06-18	Societe de Conseils de recherches et D' Applications Scientifiques S.A.S.		Corresponds to WO 1999/064420

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. 2 Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). 3 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 4 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 5 Applicant is to place a check mark here if English language translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /R.D./

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	10/561,973
Filing Date	December 22, 2005
First Named Inventor	Kazuyuki OHMOTO
Art Unit	1625
Examiner Name	Rita J DESAI
Attorney Docket Number	Q92245

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No	Foreign Document Number ²	Country Code ²	Kind Code ³	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁴
	15	9-511246	JP	A	1997-11-11	Interneuron Pharmaceuticals Inc.		Corresponds to WO 1995/026723
	16	2004-518729	JP	A	2004-06-24	Riri Aikoso Ltd., et al.		Corresponds to WO 2002/064590

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	T ⁴
	1	CAIN, M et al., "Beta-Carbolines: Synthesis and Neurochemical and Pharmacological Actions on Brain Benzodiazepine Receptors", Journal of Medicinal Chemistry, September 1982, pp. 1081-1091, Vol. 25, No. 9, American Chemical Society, Washington, US	
	2	Limbach, et al.; "Addition of Indole to Methyl 2-Chloro-2-cyclopropylideneacetate en Route to Spirocyclopropanated Analogues of Demethoxyfuremorgine C and Tadalafil"; Eur. J. Org. Chem., 2005, Vol. 3, pages 610 to 617.	
	3	L.N. YAKHONTOV, et al.; "Azaindol derivatives XXXVIII. Normal and abnormal course of reactions during 12-aza-b-carboline synthesis"; Khimiya Geterotsiklicheskikh Soedinenii, 1970, Vol. 11, pages 1550-1553.	
	4	European Search Report Dated December 3, 2009 for Application No. 05820106.2-2101/1829874 (PCT/JP2005/023450)	
	5	International Search Report (PCT/ISA/210) for PCT/JP2005/023450, dated April 11, 2006.	
	6	Chemical Abstracts Service; C. BALSAMINI, et al.; "N-benzhydryltryptamines and 1,1-diphenyltetrahydro-beta-carbolines: synthesis, x-ray crystal structure and benzodiazepine receptor affinity" XP002556789; retrieved from STN Database accession no. 1989:526474; ISSN: 0014-827X; 1989; 1 page in total.	

EXAMINER SIGNATURE

Examiner Signature	/Rita Desai/	Date Considered	10/20/2010
--------------------	--------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. 2 Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). 3 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 4 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 5 Applicant is to place a check mark here if English language translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /R.D./